GO:0031700 adrenomedullin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031700 adrenomedullin receptor binding is a molecular function describing the binding of a ligand to an adrenomedullin receptor.
• The principal adrenomedullin receptors are heterodimers of calcitonin receptor-like receptor (CRLR, gene CALCRL) and receptor activity-modifying proteins (RAMP2 or RAMP3).
• Adrenomedullin binding to AM1 (CRLR+RAMP2) and AM2 (CRLR+RAMP3) receptors activates cAMP signaling and is involved in vasodilation, angiogenesis, and cell proliferation.
• Receptor binding sites for adrenomedullin are widely distributed in the brain and peripheral tissues, correlating with CRLR and RAMP transcript levels.
• Key residues in both adrenomedullin and the receptor ectodomain mediate selective binding to AM1 versus CGRP receptors.
• Dysregulated adrenomedullin signaling is implicated in cancer, cardiovascular disease, and sepsis, making it a target for therapeutic intervention.
Description
Adrenomedullin receptor binding (GO:0031700) is a molecular function defined as the binding of a ligand to an adrenomedullin receptor. Adrenomedullin is a multifunctional peptide hormone that exerts its effects through G protein-coupled receptors formed by the calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMPs). This binding event is the first step in a signaling cascade that regulates vasodilation, angiogenesis, and cell growth. Researchers study this term to understand how adrenomedullin and related peptides interact with their receptors, and how these interactions contribute to physiology and disease. The specificity of binding is determined by the particular RAMP associated with CRLR, with RAMP2 defining the AM1 receptor and RAMP3 defining the AM2 receptor. Elucidating the molecular details of adrenomedullin receptor binding is essential for developing drugs that can selectively modulate this pathway in conditions such as cancer, cardiovascular disease, and sepsis.
adrenomedullin receptor binding At A Glance
| GO ID | GO:0031700 |
|---|---|
| GO term | adrenomedullin receptor binding |
| Ontology | molecular_function |
| Synonym | adrenomedullin receptor ligand |
| Major function | Binding to an adrenomedullin receptor, initiating downstream signaling. |
| Related receptors | CRLR (CALCRL) in complex with RAMP2 or RAMP3. |
| Ligand | Adrenomedullin peptide (ADM). |
| Signaling pathway | cAMP-mediated signaling. |
| Tissue distribution | Widely expressed in brain, peripheral tissues, and vasculature. |
What Is GO:0031700?
According to the Gene Ontology, GO:0031700 adrenomedullin receptor binding is the molecular function of binding to an adrenomedullin receptor. This means it describes the interaction between a ligand (such as the peptide adrenomedullin) and its specific receptor complex on the cell surface. The term is used to annotate gene products that physically interact with adrenomedullin receptors, including the ligand itself and any accessory proteins that directly participate in this binding event.
Why Is adrenomedullin receptor binding Important in Cell Biology?
Adrenomedullin receptor binding is a critical molecular event that initiates a wide range of physiological responses, including vasodilation, angiogenesis, and regulation of cell growth and survival. Because adrenomedullin signaling is involved in cancer progression, cardiovascular homeostasis, and inflammatory conditions such as sepsis, understanding the precise binding mechanisms is essential for therapeutic development. Moreover, the selectivity of adrenomedullin for its receptors over related peptides like CGRP depends on specific molecular interactions that are actively studied.
• Adrenomedullin receptor binding is the first step in a signaling cascade that regulates vascular tone and blood pressure.
• It plays a key role in angiogenesis and lymphangiogenesis, processes important for tumor growth and metastasis.
• Dysregulated adrenomedullin signaling has been implicated in sepsis and inflammatory diseases.
• The binding specificity of adrenomedullin to AM1 versus AM2 receptors is determined by RAMP proteins, offering targets for selective drug design.
• Adrenomedullin receptor binding sites are widely distributed in the brain, suggesting roles in neuroendocrine functions.
• Alterations in CRLR and RAMP expression levels correlate with adrenomedullin binding capacity in various tissues.
• Understanding this binding event can aid in the development of antagonists or agonists for cancer therapy.
• It is a model system for studying G protein-coupled receptor pharmacology and peptide hormone action.
What Happens During adrenomedullin receptor binding?
Ligand recognition and initial contact
In simple terms: The adrenomedullin peptide finds and docks onto its receptor on the cell surface.
Adrenomedullin, a 52-amino-acid peptide, is secreted and acts in an autocrine or paracrine manner. The first step in receptor binding involves the recognition of the receptor complex by the ligand. The receptor is a heterodimer of calcitonin receptor-like receptor (CRLR) and a receptor activity-modifying protein (RAMP), primarily RAMP2 or RAMP3. The extracellular domain of CRLR, in conjunction with the RAMP, forms the binding pocket for adrenomedullin. Specific residues in adrenomedullin, such as those in the C-terminal region, are critical for high-affinity binding to the AM1 receptor.
Conformational changes and receptor activation
In simple terms: Once bound, the receptor changes shape to send a signal inside the cell.
Binding of adrenomedullin to the CRLR-RAMP complex induces conformational changes in the receptor that lead to activation of the associated G protein, typically Gs. This activation stimulates adenylyl cyclase, increasing intracellular cAMP levels. The specificity of this activation is determined by the RAMP: RAMP2 confers adrenomedullin selectivity to the AM1 receptor, while RAMP3 forms the AM2 receptor with different binding kinetics. The binding event is reversible and subject to regulation by receptor internalization and desensitization.
Signal transduction and downstream effects
In simple terms: The signal travels inside the cell to trigger various responses like vasodilation or cell growth.
Elevated cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), leading to phosphorylation of downstream targets. This cascade results in physiological effects such as vasodilation, angiogenesis, and inhibition of apoptosis. In endothelial cells, adrenomedullin binding promotes proliferation and migration, contributing to angiogenesis. In the brain, adrenomedullin binding sites are localized in regions involved in neuroendocrine regulation.
Regulation of receptor availability
In simple terms: Cells can adjust how many receptors are on the surface, controlling sensitivity to adrenomedullin.
The expression levels of CRLR and RAMPs are regulated transcriptionally and post-transcriptionally, affecting the number of binding sites. Studies in rat tissues show that adrenomedullin binding correlates with transcript levels for CRLR and RAMPs. Hypoxia, for example, can upregulate CRLR and RAMP2 via HIF-1α, increasing adrenomedullin binding and signaling. This regulation is important in pathological conditions like cancer and ischemia.
Key Genes Involved in GO:0031700 adrenomedullin receptor binding
The following genes encode proteins that directly participate in or regulate adrenomedullin receptor binding.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADM | Encodes adrenomedullin peptide, the ligand that binds to adrenomedullin receptors. | Studied for its role in vasodilation, angiogenesis, and cancer. |
| CALCRL | Encodes calcitonin receptor-like receptor (CRLR), the core receptor subunit. | Essential for adrenomedullin and CGRP receptor function. |
| RAMP2 | Encodes receptor activity-modifying protein 2, which forms AM1 receptor with CRLR. | Determines adrenomedullin specificity; knockout is embryonic lethal. |
| RAMP3 | Encodes receptor activity-modifying protein 3, which forms AM2 receptor with CRLR. | Modulates adrenomedullin binding kinetics and trafficking. |
| GNAS | Encodes Gs alpha subunit, mediates cAMP signaling downstream of receptor activation. | Commonly mutated in endocrine tumors; affects adrenomedullin signaling. |
| ADCY | Encodes adenylyl cyclase, produces cAMP upon Gs activation. | Target for modulating adrenomedullin signaling. |
| PRKACA | Encodes catalytic subunit of PKA, a downstream effector of cAMP. | Involved in phosphorylation cascades triggered by adrenomedullin. |
| EPAC | Encodes exchange protein directly activated by cAMP, alternative effector. | Mediates PKA-independent effects of adrenomedullin. |
| HIF1A | Encodes hypoxia-inducible factor 1-alpha, regulates CRLR and RAMP expression. | Links hypoxia to increased adrenomedullin binding. |
| VEGFA | Encodes vascular endothelial growth factor A, downstream of adrenomedullin in angiogenesis. | Adrenomedullin binding promotes VEGF expression. |
| NOS3 | Encodes endothelial nitric oxide synthase, mediates vasodilation. | Adrenomedullin binding increases NO production. |
| MAPK1 | Encodes ERK2, involved in proliferative signaling. | Activated by adrenomedullin in some cell types. |
| MAPK3 | Encodes ERK1, involved in proliferative signaling. | Activated by adrenomedullin in some cell types. |
| AKT1 | Encodes AKT serine/threonine kinase 1, promotes cell survival. | Adrenomedullin binding activates PI3K/AKT pathway. |
| SRC | Encodes SRC proto-oncogene, non-receptor tyrosine kinase. | May be activated by adrenomedullin receptor binding. |
| ARRB1 | Encodes beta-arrestin 1, involved in receptor desensitization and internalization. | Regulates adrenomedullin receptor trafficking. |
| ARRB2 | Encodes beta-arrestin 2, involved in receptor desensitization and internalization. | Regulates adrenomedullin receptor trafficking. |
| RAMP1 | Encodes receptor activity-modifying protein 1, forms CGRP receptor with CRLR. | Related to adrenomedullin receptor family; binds CGRP with high affinity. |
How Is adrenomedullin receptor binding Regulated?
Adrenomedullin receptor binding is regulated at multiple levels. The expression of the receptor components CRLR and RAMPs is controlled by transcription factors such as HIF-1α, which upregulates CRLR and RAMP2 under hypoxic conditions. Additionally, receptor availability is modulated by internalization and recycling, processes mediated by beta-arrestins. The binding affinity can also be influenced by post-translational modifications of the receptor or ligand. Furthermore, the local concentration of adrenomedullin is regulated by its secretion and degradation, affecting the extent of receptor binding.
adrenomedullin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADM | Cancer, sepsis, cardiovascular disease | ADM knockout or overexpression cell lines; xenograft models |
| CALCRL | Angiogenesis, cardiovascular homeostasis | CALCRL conditional knockout mice; CRISPR point mutations in binding domain |
| RAMP2 | Embryonic vascular development, cancer | RAMP2 knockout mice (embryonic lethal); inducible knockout |
| RAMP3 | Lymphangiogenesis, cancer metastasis | RAMP3 knockout mice; overexpression in lymphatic endothelial cells |
| HIF1A | Hypoxia-driven cancer progression | HIF1A knockout cells under hypoxia; reporter assays |
Adrenomedullin receptor binding in cancer
Adrenomedullin and its receptors are overexpressed in many cancers, where they promote angiogenesis, cell proliferation, and survival. Binding of adrenomedullin to its receptor activates cAMP/PKA and PI3K/AKT pathways, contributing to tumor growth and metastasis. Hypoxia in the tumor microenvironment upregulates CRLR and RAMP2 via HIF-1α, enhancing adrenomedullin binding and signaling. Targeting this interaction is a potential therapeutic strategy.
Cardiovascular and inflammatory diseases
Adrenomedullin is a potent vasodilator, and its binding to receptors on vascular smooth muscle and endothelial cells regulates blood pressure. In sepsis, elevated adrenomedullin levels and altered receptor binding contribute to vascular dysfunction and inflammation. Polymorphisms in the ADM gene or its receptors have been associated with cardiovascular risk.
Neurological roles and potential implications
Adrenomedullin receptor binding sites are present in the brain, including regions involved in neuroendocrine and autonomic functions. Adrenomedullin has been implicated in neuroprotection and modulation of pain perception. Dysregulation may contribute to migraine and other neurological disorders, although the exact mechanisms require further study.
From adrenomedullin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of adrenomedullin receptor binding affect angiogenesis? | CRLR or RAMP2 knockout endothelial cells; tube formation assay |
| What is the effect of a point mutation in the adrenomedullin binding pocket? | CRISPR knock-in of point mutations in CALCRL or RAMP2 in cell lines |
| Can we visualize adrenomedullin receptor binding in live cells? | Tagged knock-in of CALCRL with fluorescent protein; live-cell imaging |
| Does overexpression of adrenomedullin increase tumor growth? | ADM overexpression in cancer cell lines; xenograft mouse models |
| What genes are regulated by adrenomedullin receptor binding? | RNA-seq after adrenomedullin stimulation in wild-type vs. receptor knockout cells |
| Can we screen for modulators of adrenomedullin binding? | CRISPR library screening with a cAMP reporter |
How to Study the adrenomedullin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity and receptor density | Characterizing adrenomedullin receptors in tissues |
| cAMP ELISA | Intracellular cAMP levels | Measuring receptor activation after ligand binding |
| Luciferase reporter assay | cAMP-responsive element activity | High-throughput screening for receptor modulators |
| RNA-seq | Transcriptome changes | Identifying downstream targets of adrenomedullin signaling |
| Western blot | Protein expression and phosphorylation | Detecting CRLR, RAMPs, and signaling intermediates |
| Immunofluorescence | Subcellular localization | Visualizing receptor internalization and trafficking |
| CRISPR knockout | Gene function | Determining necessity of CRLR or RAMPs for binding |
| Surface plasmon resonance | Real-time binding kinetics | Measuring affinity between adrenomedullin and receptor ectodomain |
Binding assays
Radioligand binding assays using iodinated adrenomedullin are used to measure binding affinity and receptor density in tissues or cells. These assays can be performed on membrane preparations or whole cells and are useful for characterizing receptor pharmacology.
cAMP measurement
Since adrenomedullin receptor activation primarily increases intracellular cAMP, cAMP assays (e.g., ELISA or luciferase reporter) are standard to measure receptor function after ligand binding. This method is high-throughput and suitable for screening modulators.
Transcriptomic analysis
RNA-seq can quantify expression of CRLR, RAMPs, and downstream target genes after adrenomedullin stimulation or receptor knockout. This helps identify gene networks regulated by adrenomedullin receptor binding.
Imaging and localization
Fluorescently tagged adrenomedullin or receptor subunits can be used for confocal microscopy to visualize binding and internalization in live cells. Autoradiography with radiolabeled adrenomedullin can map binding sites in tissue sections.
How CRISPR Can Be Used to Study GO:0031700 adrenomedullin receptor binding
Knockout
CRISPR knockout of CALCRL, RAMP2, or RAMP3 can abolish adrenomedullin receptor binding, providing a clean background to study the specific contributions of each subunit. Knockout cell lines are valuable for confirming receptor composition and for identifying compensatory mechanisms.
Point Mutation
CRISPR-mediated point mutations can be introduced into the adrenomedullin binding pocket of CALCRL or RAMPs to dissect the molecular determinants of ligand selectivity and affinity. For example, mutations in key residues identified by structural studies can validate their role in binding.
Knock-in
Knock-in of tagged versions of CALCRL or RAMP2 (e.g., with fluorescent or epitope tags) allows real-time visualization and biochemical isolation of receptor complexes. This approach is useful for tracking receptor trafficking and interactions.
Overexpression
Overexpression of ADM, CALCRL, or RAMPs in cell lines can enhance adrenomedullin receptor binding and downstream signaling, enabling studies of gain-of-function effects in cancer or angiogenesis models.
How EDITGENE Supports adrenomedullin receptor binding Research
Researchers studying adrenomedullin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for adrenomedullin receptor binding research.
Frequently Asked Questions About adrenomedullin receptor binding
What is adrenomedullin receptor binding?
Adrenomedullin receptor binding (GO:0031700) is the molecular function of a ligand binding to an adrenomedullin receptor, typically a heterodimer of CRLR and RAMP2 or RAMP3.
What genes are involved in adrenomedullin receptor binding?
Key genes include ADM (encoding adrenomedullin), CALCRL (encoding CRLR), and RAMP2/RAMP3 (encoding receptor activity-modifying proteins).
What is the function of adrenomedullin receptor binding?
It initiates signaling cascades that regulate vasodilation, angiogenesis, cell proliferation, and survival.
Which receptors bind adrenomedullin?
Adrenomedullin binds primarily to the AM1 receptor (CRLR + RAMP2) and AM2 receptor (CRLR + RAMP3).
How is adrenomedullin receptor binding studied?
Common methods include radioligand binding assays, cAMP measurements, and CRISPR knockout of receptor subunits.
What diseases are associated with adrenomedullin receptor binding?
Dysregulation is implicated in cancer, cardiovascular disease, sepsis, and possibly neurological disorders.
What is the role of RAMP2 in adrenomedullin receptor binding?
RAMP2 is essential for forming the AM1 receptor and confers high affinity for adrenomedullin.
Can CRISPR be used to study adrenomedullin receptor binding?
Yes, CRISPR knockout, point mutation, and knock-in can be used to dissect the function of CALCRL, RAMPs, and ADM in receptor binding.
What are the synonyms for adrenomedullin receptor binding?
The synonym is adrenomedullin receptor ligand [GO:0031700].
Where is adrenomedullin receptor binding found in the body?
Binding sites are widely distributed in the brain and peripheral tissues, including vasculature and endocrine organs.
Conclusion
Adrenomedullin receptor binding (GO:0031700) is a fundamental molecular function that mediates the diverse physiological actions of adrenomedullin. The interaction between adrenomedullin and its receptors, composed of CRLR and RAMPs, triggers cAMP signaling that regulates vascular tone, angiogenesis, and cell growth. Dysregulation of this binding is linked to cancer, cardiovascular disease, and sepsis, making it a target for therapeutic intervention. Understanding the precise molecular details of adrenomedullin receptor binding will continue to inform drug discovery and disease research.
References
- 1. Bateman RM et al.. 2016. 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.. Crit Care 20(Suppl 2):94 PMID: 27885969
- 2. Masoud GN et al.. 2015. HIF-1α pathway: role, regulation and intervention for cancer therapy.. Acta Pharm Sin B 5(5):378-89 PMID: 26579469
- 3. Juaneda C et al.. 2003. Adrenomedullin receptor binding sites in rat brain and peripheral tissues.. Eur J Pharmacol 474(2-3):165-74 PMID: 12921858
- 4. Smith DM et al.. 2002. Adrenomedullin: receptor and signal transduction.. Biochem Soc Trans 30(4):432-7 PMID: 12196109
- 5. Young A. 2005. Receptor pharmacology.. Adv Pharmacol 52:47-65 PMID: 16492540
- 6. Watkins HA et al.. 2013. Identification of key residues involved in adrenomedullin binding to the AM1 receptor.. Br J Pharmacol 169(1):143-55 PMID: 23351143
- 7. Moad HE et al.. 2013. Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins.. Protein Sci 22(12):1775-85 PMID: 24115156
- 8. Chakravarty P et al.. 2000. CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues.. Br J Pharmacol 130(1):189-95 PMID: 10781016
